169
Views
13
CrossRef citations to date
0
Altmetric
Original Articles: Research

Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3ζ recombinant gene

, , , , , , & show all
Pages 1368-1373 | Received 12 Feb 2008, Accepted 15 Mar 2008, Published online: 01 Jul 2009
 

Abstract

One of the approaches to make anti-CD20 antibody more efficient is to express this antibody on the surface of T cells. scFv from anti-CD20 antibody has been expressed on T cell surface to bind to CD20 positive cells and CD3ζ has been expressed as a fusion partner to transduct signals. T cells grafted with this chimeric scFv/CD3ζ were able to redirect grafted T cells to an MHC/Ag-independent antitumor response. To test the effects of CD28 signal on the cellular activation and antitumor effectiveness of chimeric scFv/CD3ζ modified T cells, we constructed a recombinant anti-CD20 scFv/CD28/CD3ζ gene in a retroviral vector. T cells expressing anti-CD20 scFv/CD28/CD3ζ specifically lysed CD20 positive target tumor cells and secreted not only IFN-γ but also IL-2 after binding to their target cells. Our data indicate that CD3 and CD28 signalling can be delivered in one molecule, which is sufficient for complete T cell activation without exogenous B7/CD28 costimulation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.